SELECTIVE SENSITIVITY OF SOLID TUMORS TO SURAMIN IN PRIMARY CULTURES OF TUMOR-CELLS FROM PATIENTS

被引:9
作者
CSOKA, K
NYGREN, P
GRAF, W
PAHLMAN, L
GLIMELIUS, B
LARSSON, R
机构
[1] UNIV UPPSALA HOSP,DEPT ONCOL,S-75185 UPPSALA,SWEDEN
[2] UNIV UPPSALA HOSP,DEPT SURG,S-75185 UPPSALA,SWEDEN
关键词
D O I
10.1002/ijc.2910630309
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The antineoplastic activity of suramin is currently the subject of clinical trials. We therefore used the semi-automated fluorometric microculture cytotoxicity assay (FMCA) to evaluate the cytotoxicity of suramin in vitro in primary cultures of cells from patients with hematological or solid tumors. The activity patterns of some standard cytotoxic agents were included for comparison. A total of 159 samples were tested using continuous drug exposure. Suramin showed relatively high activity against solid tumors, with colorectal, adrenal and kidney carcinomas being the most sensitive, whereas hematological malignancies were more resistant. Suramin and standard drugs showed very low cross-resistance. The results indicate that suramin is differentially active against some solid tumors with comparatively little activity against hematological tumors. The study provides an experimental motive for evaluation of suramin therapy in patients with solid tumors and exploration of less toxic suramin analogues. (C) 1995 Wiley-Liss, Inc.
引用
收藏
页码:356 / 360
页数:5
相关论文
共 29 条
[1]  
ALBERTS D, 1991, P AN M AM SOC CLIN, V10, P187
[2]  
ANDREOTTI P, 1994, P ASCO, V13, P165
[3]   SURAMIN IN ADRENOCORTICAL CANCER - LIMITED EFFICACY AND SERIOUS TOXICITY [J].
ARLT, W ;
REINCKE, M ;
SIEKMANN, L ;
WINKELMANN, W ;
ALLOLIO, B .
CLINICAL ENDOCRINOLOGY, 1994, 41 (03) :299-307
[4]   A STRUCTURE-ACTIVITY ANALYSIS OF ANTAGONISM OF THE GROWTH-FACTOR AND ANGIOGENIC ACTIVITY OF BASIC FIBROBLAST GROWTH-FACTOR BY SURAMIN AND RELATED POLYANIONS [J].
BRADDOCK, PS ;
HU, DE ;
FAN, TPD ;
STRATFORD, IJ ;
HARRIS, AL ;
BICKNELL, R .
BRITISH JOURNAL OF CANCER, 1994, 69 (05) :890-898
[5]   NEW SULFONATED DISTAMYCIN-A DERIVATIVES WITH BFGF COMPLEXING ACTIVITY [J].
CIOMEI, M ;
PASTORI, W ;
MARIANI, M ;
SOLA, F ;
GRANDI, M ;
MONGELLI, N .
BIOCHEMICAL PHARMACOLOGY, 1994, 47 (02) :295-302
[6]   CYTOTOXIC DRUG-SENSITIVITY TESTING OF TUMOR-CELLS FROM PATIENTS WITH OVARIAN-CARCINOMA USING THE FLUOROMETRIC MICROCULTURE CYTOTOXICITY ASSAY (FMCA) [J].
CSOKA, K ;
LARSSON, R ;
THOLANDER, B ;
GERDIN, E ;
DELATORRE, M ;
NYGREN, P .
GYNECOLOGIC ONCOLOGY, 1994, 54 (02) :163-170
[7]   SURAMIN, AN ACTIVE-DRUG FOR PROSTATE-CANCER - INTERIM OBSERVATIONS IN A PHASE-I TRIAL [J].
EISENBERGER, MA ;
REYNO, LM ;
JODRELL, DI ;
SINIBALDI, VJ ;
TKACZUK, KH ;
SRIDHARA, R ;
ZUHOWSKI, EG ;
LOWITT, MH ;
JACOBS, SC ;
EGORIN, MJ .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (08) :611-621
[8]   SYNERGISTIC ANTIPROLIFERATIVE ACTIVITY OF SURAMIN AND INTERFERON-ALPHA-2A AGAINST HUMAN COLORECTAL ADENOCARCINOMA CELL-LINES - IN-VITRO STUDIES [J].
FALCONE, A ;
DANESI, R ;
ZACCARO, L ;
PIERACCI, D ;
PFANNER, E ;
CIANCI, C ;
ANDREUCCETTI, M ;
MALVALDI, G ;
DELTACCA, M ;
CONTE, PF .
EUROPEAN JOURNAL OF CANCER, 1994, 30A (04) :516-520
[9]  
FALCONE A, 1995, CANCER, V75, P440, DOI 10.1002/1097-0142(19950115)75:2<440::AID-CNCR2820750205>3.0.CO
[10]  
2-3